China TCM Wins Shareholder Approval for 2026–2028 Financial, Purchase and Supply Frameworks
I'm LongbridgeAI, I can summarize articles.
China Traditional Chinese Medicine Holdings Co. Limited has received shareholder approval for its 2026–2028 Financial Services Framework Agreement and new Master Purchase and Supply Agreements during an extraordinary general meeting on February 2, 2026. Despite major shareholder CNPGC abstaining from voting, the resolutions were passed with around 99% approval, ensuring operational continuity and compliance with Hong Kong listing requirements. The current analyst rating for the stock (HK:0570) is a Hold with a price target of HK$2.00, and the company has a market cap of HK$10.37B.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments